A C Achhra1, A Mocroft2, P Reiss3, C Sabin2, L Ryom4, S de Wit5, C J Smith2, A d'Arminio Monforte6, A Phillips2, R Weber7, J Lundgren8, M G Law1. 1. Kirby Institute, UNSW Australia, Sydney, NSW, Australia. 2. Research Department of Infection & Population Health, University College London, London, UK. 3. Division of Infectious Diseases and Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands. 4. University of Copenhagen, Copenhagen, Denmark. 5. Infectious Diseases Department, Saint-Pierre University Hospital, Brussels, Belgium. 6. University of Milan Clinic of Infectious Diseases, Milan, Italy. 7. University Hospital in Zurich, Zurich, Switzerland. 8. Rigshospitalet & University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVES: The aim of the study was to assess the impact of the gain in body mass index (BMI) observed immediately after antiretroviral therapy (ART) initiation on the subsequent risk of cardiovascular disease (CVD) and diabetes. METHODS: We analysed data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study. Outcomes were development of (i) CVD (composite of myocardial infarction/stroke/coronary procedure) and (ii) diabetes. The main exposure variable was change in BMI from ART initiation (pre-ART) to 1 year after initiation (continuous variable) in treatment-naïve individuals initiating ART with no history of CVD or diabetes (for respective outcomes). BMI [weight (kg)/(height (m))(2)] was categorized as underweight (< 18.5), normal (18.5-25), overweight (25-30) and obese (> 30). Poisson regression models were fitted stratified for each pre-ART BMI category to allow for category-specific estimates of incidence rate ratio (IRR). Models were adjusted for pre-ART BMI and CD4 count, key known risk factors (time-updated where possible) and calendar year. RESULTS: A total of 97 CVD events occurred in 43,982 person-years (n = 9321) and 125 diabetes events in 43,278 person-years (n = 9193). In fully adjusted analyses for CVD, the IRR/unit gain in BMI (95% confidence interval) in the first year of ART, by pre-ART BMI category, was: underweight, 0.90 (0.60-1.37); normal, 1.18 (1.05-1.33); overweight, 0.87 (0.70-1.10), and obese, 0.95 (0.71-1.28) (P for interaction = 0.04). For diabetes, the IRR/unit gain in BMI was 1.11 (95% confidence interval 1.03 to 1.21), regardless of pre-ART BMI (P for interaction > 0.05). CONCLUSIONS: Short-term gain in BMI following ART initiation appeared to increase the longer term risk of CVD, but only in those with pre-ART BMI in the normal range. It was also associated with increased risk of diabetes regardless of pre-ART BMI.
OBJECTIVES: The aim of the study was to assess the impact of the gain in body mass index (BMI) observed immediately after antiretroviral therapy (ART) initiation on the subsequent risk of cardiovascular disease (CVD) and diabetes. METHODS: We analysed data from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study. Outcomes were development of (i) CVD (composite of myocardial infarction/stroke/coronary procedure) and (ii) diabetes. The main exposure variable was change in BMI from ART initiation (pre-ART) to 1 year after initiation (continuous variable) in treatment-naïve individuals initiating ART with no history of CVD or diabetes (for respective outcomes). BMI [weight (kg)/(height (m))(2)] was categorized as underweight (< 18.5), normal (18.5-25), overweight (25-30) and obese (> 30). Poisson regression models were fitted stratified for each pre-ART BMI category to allow for category-specific estimates of incidence rate ratio (IRR). Models were adjusted for pre-ART BMI and CD4 count, key known risk factors (time-updated where possible) and calendar year. RESULTS: A total of 97 CVD events occurred in 43,982 person-years (n = 9321) and 125 diabetes events in 43,278 person-years (n = 9193). In fully adjusted analyses for CVD, the IRR/unit gain in BMI (95% confidence interval) in the first year of ART, by pre-ART BMI category, was: underweight, 0.90 (0.60-1.37); normal, 1.18 (1.05-1.33); overweight, 0.87 (0.70-1.10), and obese, 0.95 (0.71-1.28) (P for interaction = 0.04). For diabetes, the IRR/unit gain in BMI was 1.11 (95% confidence interval 1.03 to 1.21), regardless of pre-ART BMI (P for interaction > 0.05). CONCLUSIONS: Short-term gain in BMI following ART initiation appeared to increase the longer term risk of CVD, but only in those with pre-ART BMI in the normal range. It was also associated with increased risk of diabetes regardless of pre-ART BMI.
Keywords:
HIV; body mass index; cardiovascular diseases; diabetes; highly active antiretroviral therapy; inflammation; myocardial infarction; weight gain
Authors: Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Barbara S Taylor; Kaku So-Armah; Janet P Tate; Vincent C Marconi; John R Koethe; Roger J Bedimo; Adeel A Butt; Cynthia L Gibert; Matthew B Goetz; Maria C Rodriguez-Barradas; Julie A Womack; Mariana Gerschenson; Vincent Lo Re; David Rimland; Michael T Yin; David Leaf; Russell P Tracy; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: Julie A Ake; Christina S Polyak; Trevor A Crowell; Francis Kiweewa; Michael Semwogerere; Lucas Maganga; Emmanuel Bahemana; Jonah Maswai; Rither Langat; John Owuoth; Solomon Otieno; Babajide Keshinro; Allahna L Esber; Michelle Liu; Leigh Anne Eller; Kavitha Ganesan; Ajay P Parikh; Tiffany E Hamm; Merlin L Robb; Patrick W Hickey; Victor G Valcour; Nelson L Michael Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Melissa Herrin; Janet P Tate; Kathleen M Akgün; Adeel A Butt; Kristina Crothers; Matthew S Freiberg; Cynthia L Gibert; David A Leaf; David Rimland; Maria C Rodriguez-Barradas; Chris B Ruser; Kevan C Herold; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2016-10-01 Impact factor: 3.731
Authors: Vidya Mave; Kristine M Erlandson; Nikhil Gupte; Ashwin Balagopal; David M Asmuth; Thomas B Campbell; Laura Smeaton; Nagalingeswaran Kumarasamy; James Hakim; Breno Santos; Cynthia Riviere; Mina C Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Srikanth Tripathy; Noluthando Mwelase; Sima Berendes; Bruno B Andrade; David L Thomas; Robert C Bollinger; Amita Gupta Journal: J Infect Dis Date: 2016-03-08 Impact factor: 5.226